Business · 09/03/2026
FDA Releases Draft Guidance for Responding to Form 483 Observations
The FDA is releasing a draft guidance to help pharmaceutical manufacturers respond to FDA Form 483 observations, aimed at ensuring compliance with current good manufacturing practice (CGMP) requirements.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →